Literature DB >> 30526799

Canadian consensus algorithm for erectile rehabilitation following prostate cancer treatment.

Dean S Elterman1, Anika R Petrella1, Lauren M Walker2, Brandon Van Asseldonk1, Leah Jamnicky1, Gerald B Brock3, Stacy Elliott2, Antonio Finelli1, Jerzy B Gajewski4, Keith A Jarvi5, John Robinson6, Janet Ellis7, Shaun Shepherd1, Hossein Saadat1, Andrew Matthew1.   

Abstract

INTRODUCTION: The present descriptive analysis carried out by a pan-Canadian panel of expert healthcare practitioners (HCPs) summarizes best practices for erectile rehabilitation following prostate cancer (PCa) treatment. This algorithm was designed to support an online sexual health and rehabilitation e-clinic (SHARe-Clinic), which provides biomedical guidance and supportive care to Canadian men recovering from PCa treatment. The implications of the algorithm may be used inform clinical practice in community settings.
METHODS: Men's sexual health experts convened for the TrueNTH Sexual Health and Rehabilitation Initiative Consensus Meeting to address concerns regarding erectile dysfunction (ED) therapy and management following treatment for PCa. The meeting brought together experts from across Canada for a discussion of current practices, latest evidence-based literature review, and patient interviews.
RESULTS: An algorithm for ED treatment following PCa treatment is presented that accounts for treatment received (surgery or radiation), degree of nerve-sparing, and level of pro-erectile treatment invasiveness based on patient and partner values. This algorithm provides an approach from both a biomedical and psychosocial focus that is tailored to the patient/partner presentation. Regular sexual activity is recommended, and the importance of partner involvement in the treatment decision-making process is highlighted, including the management of partner sexual concerns.
CONCLUSIONS: The algorithm proposed by expert consensus considers important factors like the type of PCa treatment, the timeline of erectile recovery, and patient values, with the goal of becoming a nationwide standard for erectile rehabilitation following PCa treatment.

Entities:  

Year:  2018        PMID: 30526799      PMCID: PMC6737730          DOI: 10.5489/cuaj.5653

Source DB:  PubMed          Journal:  Can Urol Assoc J        ISSN: 1911-6470            Impact factor:   1.862


  45 in total

1.  Discussing the sexual consequences of treatment in radiotherapy and urology consultations with couples affected by prostate cancer.

Authors:  Liz Forbat; Isabella White; Sylvie Marshall-Lucette; Daniel Kelly
Journal:  BJU Int       Date:  2011-06-01       Impact factor: 5.588

2.  Postprostatectomy erectile dysfunction: the role of penile rehabilitation.

Authors:  Brian P Defade; Culley C Carson; Michael J Kennelly
Journal:  Rev Urol       Date:  2011

Review 3.  Psychosocial perspectives on sexual recovery after prostate cancer treatment.

Authors:  Lauren M Walker; Richard J Wassersug; John W Robinson
Journal:  Nat Rev Urol       Date:  2015-03-10       Impact factor: 14.432

4.  Penile rehabilitation with phosphodiesterase type 5 inhibitors after nerve-sparing radical prostatectomy: are we targeting the right patients?

Authors:  Fabio Castiglione; Alessandro Nini; Alberto Briganti
Journal:  Eur Urol       Date:  2013-12-25       Impact factor: 20.096

5.  The association between erectile dysfunction and depressive symptoms in men treated for prostate cancer.

Authors:  Christian J Nelson; John P Mulhall; Andrew J Roth
Journal:  J Sex Med       Date:  2010-12-14       Impact factor: 3.802

6.  Predicting participation in and successful outcome of a penile rehabilitation programme using a phosphodiesterase type 5 inhibitor with a vacuum erection device after radical prostatectomy.

Authors:  Masaki Kimura; Jorge R Caso; Lionel L Bañez; Bridget F Koontz; Leah Gerber; Cagri Senocak; Craig F Donatucci; Zeljko Vujaskovic; Judd W Moul; Thomas J Polascik
Journal:  BJU Int       Date:  2012-04-23       Impact factor: 5.588

7.  Exploring the role of the partner in couples' sexual recovery after surgery for prostate cancer.

Authors:  Daniela Wittmann; Marsha Carolan; Barbara Given; Ted A Skolarus; Lawrence An; Ganesh Palapattu; James E Montie
Journal:  Support Care Cancer       Date:  2014-04-13       Impact factor: 3.603

8.  Adherence to initial PDE-5 inhibitor treatment: randomized open-label study comparing tadalafil once a day, tadalafil on demand, and sildenafil on demand in patients with erectile dysfunction.

Authors:  Jacques Buvat; Hartwig Büttner; Konstantinos Hatzimouratidis; Pedro A S Vendeira; Ignacio Moncada; Michael Boehmer; Carsten Henneges; Frank G Boess
Journal:  J Sex Med       Date:  2013-04-02       Impact factor: 3.802

9.  Effects of tadalafil treatment on erectile function recovery following bilateral nerve-sparing radical prostatectomy: a randomised placebo-controlled study (REACTT).

Authors:  Francesco Montorsi; Gerald Brock; Jens-Uwe Stolzenburg; John Mulhall; Ignacio Moncada; Hitendra R H Patel; Daniel Chevallier; Kazimierz Krajka; Carsten Henneges; Ruth Dickson; Hartwig Büttner
Journal:  Eur Urol       Date:  2013-10-13       Impact factor: 20.096

10.  Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012.

Authors:  Jacques Ferlay; Isabelle Soerjomataram; Rajesh Dikshit; Sultan Eser; Colin Mathers; Marise Rebelo; Donald Maxwell Parkin; David Forman; Freddie Bray
Journal:  Int J Cancer       Date:  2014-10-09       Impact factor: 7.396

View more
  2 in total

Review 1.  Recommendations on Weight Loss and Healthy Lifestyle in Prostate Cancer Clinical Guidelines: A Systematic Review.

Authors:  Mario Rivera-Izquierdo; Virginia Martínez-Ruiz; José Juan Jiménez-Moleón
Journal:  Int J Environ Res Public Health       Date:  2022-01-27       Impact factor: 3.390

2.  Openness to Using an External Penile Prosthesis for Maintaining Sexual Intimacy by Individuals with Erectile Dysfunction: A Cross-Sectional Study.

Authors:  Fong Fu; Cassian J Duthie; Erik Wibowo; Richard J Wassersug; Lauren M Walker
Journal:  Sex Med       Date:  2022-08-26       Impact factor: 2.523

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.